The acquisition of Shockwave (SWAV) accelerates Johnson & Johnson MedTech’s ongoing efforts to increase its presence in high-growth markets with unmet need, while expanding its reach and scale globally. The proposed transaction adds a high-performing business in an underpenetrated category with a strong pipeline and an attractive growth and margin profile. The transaction is expected to accelerate revenue growth for both Johnson & Johnson (JNJ)and Johnson & Johnson MedTech. Shockwave is ultimately expected to become Johnson & Johnson MedTech’s thirteenth priority platform, as defined by annual sales of at least $1B.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Paging Dr. Nvidia (NASDAQ:NVDA): AI and Healthcare
- J&J to pay $75M to settle $6B baby powder lawsuit, Bloomberg reports
- J&J to pay $75M to settle Mississipi talc lawsuit, Bloomberg says
- Judge gives J&J new chance to contest evidence on talc products, Reuters says
- Piper says competitive process could materialize for ShockWave
